| 0.8288 0.018 (2.19%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.01 | 1-year : | 1.06 |
| Resists | First : | 0.86 | Second : | 0.9 |
| Pivot price | 0.83  |
|||
| Supports | First : | 0.79 | Second : | 0.66 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.83  |
| MA(100) : | 0.93 |
MA(250) : | 0.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.7 |
D(3) : | 21.8 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 1.75 | Low : | 0.74 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACHL ] has closed above bottom band by 40.3%. Bollinger Bands are 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.83 - 0.84 | 0.84 - 0.84 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.82 - 0.83 | 0.83 - 0.84 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Wed, 24 Jul 2024
Head to Head Analysis: X4 Pharmaceuticals (NASDAQ:XFOR) & Achilles Therapeutics (NASDAQ:ACHL) - Defense World
Wed, 24 Jul 2024
Achilles Therapeutics (NASDAQ:ACHL) Stock Price Up 1.1% - Defense World
Wed, 22 May 2024
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Fri, 17 May 2024
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Yahoo Finance
Thu, 04 Apr 2024
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 57.2 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 28 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.1 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.52 |
| PEG Ratio | -0.2 |
| Price to Book value | 0.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|